ArticleEClinicalMedicine2022

S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial.

Yihebali Chi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.